Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Saved in:
Bibliographic Details
Published in:Hematological oncology Vol. 37; no. S2; pp. 86 - 87
Main Authors: Ghia, P., Pluta, A., Wach, M., Lysak, D., Kozak, T., Simkovic, M., Kaplan, P., Kraychok, I., Illes, A., De La Serna, J., Dolan, S., Campbell, P., Musuraca, G., Jacob, A., Avery, E.J., Lee, J.H., Chen, T., Liang, W., Patel, P., Jurczak, W.
Format: Journal Article
Language:English
Published: Chichester Wiley Subscription Services, Inc 01-06-2019
Subjects:
Chronic lymphocytic leukemia
Immunotherapy
Leukemia
Lymphatic leukemia
Monoclonal antibodies
Rituximab
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.54_2629